A persuasive graph still requires a biological explanation

Bloating often creates a powerful desire for a visible explanation. A breath-test graph seems to provide one: a line rises, a threshold is crossed and a complex set of symptoms acquires a name. Yet the graph measures gases in exhaled breath after a test substance has been swallowed. It does not directly photograph bacteria, identify every organism or show precisely where each gas molecule was produced. Interpreting it requires a model of digestion, absorption and movement through the bowel.

Small intestinal bacterial overgrowth, or SIBO, is a recognised clinical problem in some settings, particularly when conditions predispose to intestinal stasis or malabsorption. That does not establish it as the explanation for every case of abdominal discomfort. The distinction matters because a label often brings an intervention with it. A test that is weakly connected to the original clinical question can create considerable certainty while leaving the real cause of symptoms unresolved.

I would approach the test as an attempt to answer a defined question rather than an invitation to reorganise life around a diagnosis obtained from a graph alone. Why is SIBO suspected in this particular person? What else has been considered? What will change if the result is positive or negative? When those questions are clear, uncertainty becomes something to manage rather than something to conceal.

Evidence: glucose, lactulose and intestinal transit

European hydrogen and methane breath-test guidance explains that glucose and lactulose have different properties. Glucose is absorbed in the upper small bowel and may miss more distal bacterial activity. Lactulose is not absorbed and eventually reaches colonic organisms. The timing of fermentation therefore depends partly on how quickly the test substance moves. An early rise can reflect early colonic fermentation caused by rapid transit, rather than proving excessive bacterial activity in the small bowel.

The European guideline recognises false-positive and false-negative results and advises interpreting a positive result in light of the individual’s pre-test probability. It favours glucose over lactulose in certain non-surgical settings when transit is not independently measured, because of the false-positive problem. This is a clinical-method question, not an instruction to choose and interpret a home test without professional input. The test substance, collection method and interpretive protocol all matter.

The distinction between location and timing is useful beyond this particular test. When a measurement is used as an indirect signal of another process, anything that changes the route between the process and the measurement can change the conclusion. A neat numerical threshold cannot remove that dependency. It may standardise reporting while still leaving uncertainty about what the reported event means in an individual person.

Evidence: why respected guidance can differ

The American Gastroenterological Association’s clinical update states that the definition of SIBO lacks precision and consistency. It notes controversy around its role in IBS and limited evidence to guide antibiotic strategies. It also emphasises identifying underlying causes and correcting nutritional problems where relevant. This acknowledges a legitimate clinical condition while resisting the temptation to use the term as a universal explanation for common symptoms.

A 2024 practice update endorsed by the European and American neurogastroenterology societies takes a particularly critical view of extending the SIBO hypothesis and breath testing into IBS. It argues that the hypothesis remains unproven and that unreliable testing has encouraged injudicious antibiotic use. This criticism is directed at a specific extension of the model; it does not erase the longstanding problem of bacterial overgrowth in people with predisposing structural or motility conditions.

The ACG guideline, by contrast, describes selected diagnostic uses of breath testing, with recommendations frequently based on low or very low certainty. This is why a discussion about test suitability should include the strength of evidence, rather than a simple claim that all specialists agree. Different recommendations are not permission to select whichever conclusion feels most reassuring. They are a reason to ask how the proposed test fits the actual clinical setting.

Practical implications: preparation is part of the measurement

The North American consensus describes several preparation factors that affect breath gases, including recent antibiotics, diet before the test, fasting, smoking and physical activity during collection. It also discusses medicines that alter transit and acknowledges uncertainty about probiotics and prebiotics. Preparation is not merely an administrative hurdle: the result is being interpreted against assumptions about what happened before and during the measurement.

Obtain the written instructions from the service carrying out the test and discuss practical conflicts before the appointment. Do not stop prescribed medicines or defer necessary antibiotics independently in order to obtain a more convenient test date. If treatment for an infection is needed, the infection takes priority and the clinical team can decide how testing should be rescheduled. Where fasting or medicine changes could be unsafe, the service needs to know that in advance.

If preparation was incomplete, report it honestly. Concealing a meal, a recent antibiotic course or difficulty with the collection technique does not protect the result; it removes information needed to judge reliability. Ask whether the test remains interpretable or should be rearranged. The goal is not to produce a positive result, a negative result or a perfect-looking curve. It is to obtain information that can support a sound decision.

Practical implications: distinguish methane terminology and symptom meaning

The ACG guideline explains why methane-associated findings are often described as intestinal methanogen overgrowth, or IMO, rather than SIBO. Methanogens belong to Archaea, not bacteria, and are not restricted to the small intestine. A label that implies a precise location can therefore be misleading. If methane is reported, ask what the finding means in relation to the symptom pattern and which interpretation the laboratory actually used.

This is also a reason to avoid treating every numerical detail as a separate disease. A report may contain several measurements, reference ranges and interpretive comments. More abnormal-looking items do not necessarily mean several independently confirmed diagnoses. Ask the clinician to explain the main conclusion in ordinary language, the degree of confidence in it and which part of the history makes that conclusion plausible.

Symptoms remain important even when a breath test is negative, equivocal or disputed. Bloating can warrant further assessment without requiring SIBO to be the final explanation. A careful plan can consider alternative diagnoses and symptom-focused management while acknowledging that the original mechanism remains uncertain. Being honest about uncertainty should not mean abandoning the person who still feels unwell.

Practical implications: a treatment response does not settle the diagnosis

The AGA update notes that improvement of IBS symptoms with a poorly absorbed antibiotic does not by itself confirm that SIBO, or its eradication, caused that improvement. An intervention can affect several processes at once, and symptoms can fluctuate for other reasons. The conclusion must be narrower than the experience: someone improved after treatment, but the precise mechanism may remain unresolved.

Antibiotic treatment is a clinical decision, not a self-experiment to repeat whenever discomfort returns. The ACG guideline urges caution because of adverse reactions, resistant organisms and opportunistic infection, including C. difficile. The appropriate conversation concerns whether the diagnosis is sufficiently supported, what outcome is expected and how response will be reviewed. There is no antibiotic dose, combination or repeat-course schedule recommended in this article.

Likewise, the phrase natural antimicrobial should not bypass the same questions about evidence and safety. A supplement is not validated because it is described as gentler, and a restrictive food plan is not justified simply because symptoms are frustrating. Bring any products or major dietary changes to the treating team for review. A coherent approach makes interventions accountable to outcomes rather than allowing each unsuccessful intervention to generate another untested explanation.

Limits and unanswered questions: use uncertainty constructively

Important unanswered questions concern normal small-intestinal microbial populations, how best to sample them and which test findings reliably identify people who benefit from treatment. The absence of a simple perfect test is not evidence that symptoms are imaginary. It means the clinical conclusion should be expressed with the degree of confidence the evidence supports, and reviewed when new information appears.

My broader Nicolaev Medicine framework values the relationship between the microbiome and the person’s wider biological context. In this discussion that means resisting a single-cause story when the evidence is incomplete. The framework is an author perspective, not a validated alternative to gastroenterological assessment. Claims about frequency, energetic balance or microbial intelligence cannot resolve the technical limitations of a breath test or establish a treatment effect.

A useful final plan is specific even when the explanation is provisional: who will interpret the report, what action is agreed, how symptoms and function will be followed and when the conclusion should be reconsidered. Seek prompt clinical assessment for concerning or worsening symptoms rather than assuming they are another episode of a previously assigned label. The purpose of a diagnostic name is to improve care, not to make every future symptom fit its boundaries. If the label has become more certain in conversation than it was in the original report, return to that report together. Clarifying what was demonstrated, what was inferred and what was merely suggested can prevent a provisional possibility from quietly becoming a permanent assumption.

Related reading

Author and medical note

Written by . This is general educational writing and author analysis, not a personal diagnosis or treatment plan. Discuss symptoms, treatment changes and supplement interactions with a qualified clinician. No independent medical review is claimed.

References

  1. Hammer and colleagues: European guideline on hydrogen and methane breath tests, 2022
  2. Rezaie and colleagues: Hydrogen and Methane-Based Breath Testing—North American Consensus, 2017
  3. AGA: Diagnosis and management of small intestinal bacterial overgrowth, 2020
  4. Pimentel and colleagues: ACG Clinical Guideline—Small Intestinal Bacterial Overgrowth, 2020
  5. Critical appraisal of the SIBO hypothesis and breath testing: ESNM/ANMS clinical practice update, 2024
  6. American College of Gastroenterology: Small Intestinal Bacterial Overgrowth, patient guidance

Gabriel Nicolaev – CyGuru